To test if STL001 can sensitize ovarian cancer (OVCAR-8, ES-2) cells and TNBC (HCC1143) to doxorubicin, OVCAR-8, ES-2 and HCC1143 cells were treated with sublethal concentrations of doxorubicin, display a significant increase in FOXM1 protein abundance, whereas the addition of STL001 in combination with doxorubicin efficiently prevented FOXM1 activation, resulting in decreased FOXM1 protein levels and potent induction of apoptotic cell death (indicated by caspase-3 cleavage) when compared with cells treated with doxorubicin chemotherapy alone (Fig. 6F, H). This evidence concerns the gene CASP3 and ovarian cancer.